Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026

Ardelyx (Nasdaq: ARDX) announced an abstract on IBS-C treatment patterns accepted for poster presentation at Digestive Disease Week (DDW) 2026 in Chicago, May 2-5.

Rhea-AI Summary

Ardelyx (Nasdaq: ARDX) announced an abstract on IBS-C treatment patterns accepted for poster presentation at Digestive Disease Week (DDW) 2026 in Chicago, May 2-5. The poster (Sa1729) displays May 2, 2026, 12:30-1:30 PM CT. Ardelyx also sponsors a Product Theater on May 5 at 3:00 PM CT.

The Product Theater, led by Darren Brenner, MD, will discuss IBS-C pathophysiology, case studies, and practical strategies to optimize care for adults with IBS-C.

Argus Apr 23 session

-1.00% close to close Open Argus

Details

News Market Reaction – ARDX

In the Apr 23 session, ARDX declined 1.00%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Ardelyx’s continued engagement in IBS-C through a DDW 2026 poster on tr...

Analysis

This announcement highlights Ardelyx’s continued engagement in IBS-C through a DDW 2026 poster on treatment patterns and a Product Theater targeting symptom management. It follows a March publication showing earlier and sustained IBS-C relief with tenapanor, as well as recent leadership appointments. Investors may watch for how these scientific and educational efforts support broader clinical adoption and upcoming milestones like the scheduled Q1 2026 earnings release.

Key Figures

DDW 2026 dates: May 2–5, 2026 Poster display time: May 2, 2026, 12:30–1:30 PM CT Product Theater time: May 5, 2026, 3:00 PM CT +5 more

DDW 2026 dates

May 2–5, 2026

Digestive Disease Week conference schedule in Chicago

Poster display time

May 2, 2026, 12:30–1:30 PM CT

IBS-C treatment factors poster session Sa1729

Product Theater time

May 5, 2026, 3:00 PM CT

“IBS-C: Identifying and Managing the Symptoms” session at DDW

Ettenberg direct holdings

237,000 shares

Form 3 initial statement of beneficial ownership

Ettenberg stock options

355,000 options at $6.30

Form 3 option grant expiring April 20, 2036

CEO sale Feb 24

41,666 shares at $6.255

Form 4 open-market sale under Rule 10b5-1 plan

Director Mott purchase

333,333 shares at $5.839

Form 4 open-market purchase on Feb 23, 2026

Market cap

$1,461,674,665

Equity value around time of DDW 2026 poster news

Historical Context

5 past events · Latest: Apr 20

5 events

1. Apr 20

   Leadership appointment

   24h Move

   -2.3%

   New Chief Legal Officer appointed to lead legal and compliance functions.

2. Apr 16

   Earnings date notice

   24h Move

   -0.3%

   Scheduled Q1 2026 earnings release and investor webcast announcement.

3. Apr 01

   Leadership appointment

   24h Move

   +2.0%

   New Chief Medical Officer with late-stage development experience appointed.

4. Mar 12

   Patient advocacy awards

   24h Move

   -5.5%

   Recognition of five chronic kidney disease patient advocates with awards.

5. Mar 09

   Clinical data publication

   24h Move

   -0.8%

   Peer-reviewed article showing earlier and sustained IBS-C symptom relief.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

irritable bowel syndrome with constipation, ibs-c, gastrointestinal, healthcare resource utilization, +2 more

6 terms

irritable bowel syndrome with constipation medical

"patient characteristics associated with irritable bowel syndrome with constipation (IBS-C) treatment"

Irritable bowel syndrome with constipation (IBS-C) is a chronic digestive condition characterized by recurring abdominal discomfort and infrequent, hard stools—like a traffic jam in the gut that disrupts normal bowel movements. It matters to investors because large numbers of affected patients, limited effective treatments, and ongoing drug and device development create potential market opportunity and influence healthcare spending, reimbursement decisions, and the valuation of companies tackling this unmet need.

ibs-c medical

"Irritable Bowel Syndrome with Constipation (IBS-C) Treatment ChangesAuthors"

Irritable bowel syndrome with constipation (IBS‑C) is a chronic digestive disorder marked by recurring stomach pain and infrequent or hard bowel movements. For investors, it matters because treatments and diagnostics for IBS‑C represent a sizable, ongoing market opportunity driven by patient demand, potential for new drug approvals, and pricing/reimbursement dynamics — like investing in better tools that relieve a common, long‑term household problem.

gastrointestinal medical

"impact on gastrointestinal (GI) related healthcare resource utilization (HCRU)"

Gastrointestinal describes the stomach and intestines and the processes that break down food and absorb nutrients — think of it as the body’s food‑processing and waste‑handling system. For investors, gastrointestinal matters because drugs, devices, or illnesses that affect this system can drive clinical trial outcomes, regulatory decisions, treatment demand and safety concerns, all of which can materially influence revenue, costs and risk for healthcare companies.

healthcare resource utilization medical

"impact on gastrointestinal (GI) related healthcare resource utilization (HCRU)"

Healthcare resource utilization is the measurement of how often and how intensively medical services and products are used—things like hospital stays, doctor visits, tests, medications and medical devices. For investors it shows demand patterns, cost drivers and potential revenue for providers and suppliers; think of it like tracking household electricity use to predict bills, spot growth areas and plan investments in capacity or new products.

hcru medical

"related healthcare resource utilization (HCRU), has been accepted as a poster presentation"

Health care resource utilization (HCRU) measures how much medical care a group of patients uses—things like doctor visits, hospital days, tests, and medications. For investors, HCRU is a practical way to estimate the real-world cost burden and demand for treatments or services: like checking how often customers use a product to predict future sales, higher HCRU can signal larger market need or greater cost savings from a new therapy.

pathophysiology medical

"The session will explore the pathophysiology of IBS-C, examine patient case studies"

Pathophysiology is the study of how and why diseases develop and affect the body’s normal functions. It explores the changes that occur in the body’s systems when illness strikes, much like understanding how a malfunction in a machine causes it to break down. Recognizing these processes helps identify potential problems early and develop effective treatments, which can influence how investors assess health-related industries and innovations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced an abstract, exploring the patient characteristics associated with irritable bowel syndrome with constipation (IBS-C) treatment patterns and their impact on gastrointestinal (GI) related healthcare resource utilization (HCRU), has been accepted as a poster presentation at the upcoming Digestive Disease Week Conference (DDW), to be held May 2-5, 2026, in Chicago.

Information regarding DDW can be found here.

Patient Factors Associated with Irritable Bowel Syndrome with Constipation (IBS-C) Treatment Changes
Authors: Alan Fossa, Kyle Staller, Lavanya Viswanathan, Asma Khapra, Luisa Scott
Poster: Sa1729
Display Time: May 2, 2026, 12:30 - 1:30 PM CT

In addition to the poster presentation during DDW, Ardelyx is sponsoring a Product Theater titled “IBS-C: Identifying and Managing the Symptoms,” on May 5 at 3:00 PM CT, where Darren Brenner, MD will lead an engaging clinical discussion on managing adult patients with IBS-C. The session will explore the pathophysiology of IBS-C, examine patient case studies, and discuss practical strategies for identifying when and how to optimize care for patients who may not be achieving adequate symptom relief.

About IBSRELA® (tenapanor)
IBSRELA (tenapanor) is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium. By inhibiting NHE3 on the apical surface of the enterocytes, tenapanor reduces absorption of sodium from the small intestine and colon, thus retaining luminal water content, which accelerates intestinal transit time and results in a softer stool consistency. IBSRELA has also been shown to reduce abdominal pain by decreasing visceral hypersensitivity and by decreasing intestinal permeability in animal models. In a rat model of colonic hypersensitivity, tenapanor reduced visceral hyperalgesia and normalized colonic sensory neuronal excitability.

About Irritable Bowel Syndrome with Constipation (IBS-C)
Irritable bowel syndrome with constipation (IBS-C) is a gastrointestinal disorder characterized by both abdominal pain and altered bowel movements, estimated to affect 12 million people in the U.S. IBS-C is associated with significantly impaired quality of life, reduced productivity, and substantial economic burden.

IMPORTANT SAFETY INFORMATION (IBSRELA)

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS IBSRELA is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.

CONTRAINDICATIONS

• IBSRELA is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
• IBSRELA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

WARNINGS AND PRECAUTIONS
Risk of Serious Dehydration in Pediatric Patients

• IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years).
• Avoid the use of IBSRELA in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of IBSRELA in patients 6 years to less than 12 years of age.

Diarrhea
Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients. If severe diarrhea occurs, suspend dosing and rehydrate patient.

MOST COMMON ADVERSE REACTIONS
The most common adverse reactions in IBSRELA-treated patients (incidence ≥2% and greater than placebo) were: diarrhea (16% vs 4% placebo), abdominal distension (3% vs <1%), flatulence (3% vs 1%) and dizziness (2% vs <1%).

INDICATION
IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.

Please see full Prescribing Information, including Boxed Warning, for additional risk information.

About Ardelyx

Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The company’s pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx works with its partners to develop and commercialize its products outside of the United States. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor Contact:
Lisa Caperelli
SVP, Investor Relations & Corporate Communications
lcaperelli@ardelyx.com

Media Contact:
Lindsey Manuel
Associate Director, Corporate Communications
lmanuel@ardelyx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When and where will Ardelyx present its IBS-C poster at DDW 2026 (ARDX)?

Ardelyx will present the poster on May 2, 2026, 12:30-1:30 PM CT at DDW 2026 in Chicago. According to the company, the poster ID is Sa1729 and will explore patient characteristics and IBS-C treatment patterns and GI-related HCRU.

What is the title and focus of the ARDX poster accepted for Digestive Disease Week 2026?

The poster is titled Patient Factors Associated with Irritable Bowel Syndrome with Constipation (IBS-C) Treatment Changes. According to the company, it examines patient characteristics linked to treatment patterns and their impact on gastrointestinal healthcare resource utilization.

What will Ardelyx cover in the DDW Product Theater on May 5, 2026 (ARDX)?

The Product Theater will cover IBS-C pathophysiology, patient case studies, and strategies to optimize care for adults with IBS-C. According to the company, Darren Brenner, MD will lead clinical discussion and practical approaches for patients not achieving adequate symptom relief.

Who are the listed authors on the ARDX poster at DDW 2026 and what is the poster ID?

Authors listed include Alan Fossa, Kyle Staller, Lavanya Viswanathan, Asma Khapra, and Luisa Scott. According to the company, the poster ID is Sa1729 and will be displayed during DDW on May 2, 2026.

How can investors or clinicians access Ardelyx’s DDW presentation materials (ARDX)?

Poster details and Product Theater information will be available at DDW 2026 in Chicago and through conference materials. According to the company, attendees can view poster Sa1729 on May 2 and attend the Product Theater on May 5 at 3:00 PM CT.